Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Vaccine|April 22, 2019
HPV-specific antibodies at the oral cavity up to 30 months after the start of vaccination with the quadrivalent HPV vaccine among mid-adult aged menKatherine H Parker, Troy J Kemp, Kimberly Isaacs-Soriano, et al.
Vaccine|April 4, 2019
Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative menLigia A Pinto, Timothy J Wilkin, Troy J Kemp, et al.
Vaccine|January 19, 2011
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protectionTroy J Kemp, Allan Hildesheim, Mahboobeh Safaeian, et al.
Vaccine|November 6, 2012
Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®)Troy J Kemp, Mahboobeh Safaeian, Allan Hildesheim, et al.
The Journal of Infectious Diseases|August 12, 2016
Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine TrialLigia A Pinto, Troy J Kemp, B Nelson Torres, et al.
Vaccine|August 10, 2021
Increases in HPV-16/18 antibody avidity and HPV-specific memory B-cell response in mid-adult aged men post-dose three of the quadrivalent HPV vaccineCheryl N Miller, Troy J Kemp, Martha Abrahamsen, et al.
Cancer Prevention Research (Philadelphia, Pa.)|November 6, 2013
Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine TrialMahboobeh Safaeian, Carolina Porras, Yuanji Pan, et al.
Human Vaccines & Immunotherapeutics|April 11, 2013
Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine TrialMahboobeh Safaeian, Troy J Kemp, David Yuanji Pan, et al.
Journal of the National Cancer Institute|September 28, 2017
Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT TrialMahboobeh Safaeian, Joshua N Sampson, Yuanji Pan, et al.
Human Vaccines & Immunotherapeutics|December 9, 2014
Comparison of adaptive and innate immune responses induced by licensed vaccines for Human PapillomavirusDouglas M Herrin, Emily E Coates, Pamela J Costner, et al.
Pageof 2